Literature DB >> 15554244

The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man.

Ursula Breyer-Pfaff1.   

Abstract

Amitriptyline (AT), the most widely used tricyclic antidepressant, undergoes oxidative metabolism in the side chain with production of the secondary amine nortriptyline (NT), a primary amine, and the N-oxide amitriptylinoxide (AT-NO); in addition, direct conjugation leads to a quaternary ammonium-linked glucuronide. Hydroxylation of AT or NT at the ethylene bridge of the central seven-membered ring results in four isomeric alcohols and occurs with high stereo- and enantioselectivity, the (-)-(E)-10-hydroxy compounds usually being the major products. The disposition of the alcohols is also partially enantioselective, for instance with regard to glucuronidation and reversible oxidation to ketones. Introduction of a second hydroxy group results in isomeric glycols. Oxidative attack at an aromatic ring is a minor pathway leading to dihydrodiols and phenols. Numerous metabolites originate by combinations of reactions in the ring system and the side chain. AT-NO is by about one-third excreted in unchanged form or as 10-hydroxy derivative; the major part is reduced to AT and metabolized further. The review covers current knowledge on the enzymes participating in the individual pathways. Their quantitative importance is inferred from kinetic studies in volunteers and patients and from experiments in vitro. Clinical consequences of biochemical findings mainly derive from the impact of the polymorphic CYP2D6 mediating (-)-(E)-10-hydroxylation and from its potential inhibition by other psychoactive drugs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554244     DOI: 10.1081/dmr-200033482

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  14 in total

1.  Individual variations of amitriptyline biotransformation examined in scalp hair samples.

Authors:  Detlef Thieme; Dagmar Schmid; Hans Sachs
Journal:  Forensic Sci Med Pathol       Date:  2007-09-06       Impact factor: 2.007

2.  Kinetic modelling for the assay of nortriptyline hydrochloride using potassium permanganate as oxidant.

Authors:  Nafisur Rahman; Sumaiya Khan
Journal:  AAPS PharmSciTech       Date:  2014-11-08       Impact factor: 3.246

Review 3.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

4.  Influence of ABCB1 (P-glycoprotein) haplotypes on nortriptyline pharmacokinetics and nortriptyline-induced postural hypotension in healthy volunteers.

Authors:  Berit Packert Jensen; Rebecca Lee Roberts; Ritva Vyas; Gitte Bonke; David L Jardine; Evan James Begg
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

5.  The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population.

Authors:  Jónrit Halling; Pál Weihe; Kim Brosen
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  A Model Based Cost-Effectiveness Analysis of Routine Genotyping for CYP2D6 among Older, Depressed Inpatients Starting Nortriptyline Pharmacotherapy.

Authors:  Elizabeth J J Berm; Judith J Gout-Zwart; Jos Luttjeboer; Bob Wilffert; Maarten J Postma
Journal:  PLoS One       Date:  2016-12-29       Impact factor: 3.240

8.  A Study on CYP2C19 and CYP2D6 Polymorphic Effects on Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Koreans.

Authors:  S Ryu; S Park; J H Lee; Y R Kim; H S Na; H S Lim; H Y Choi; I Y Hwang; J G Lee; Z W Park; W Y Oh; J M Kim; S E Choi
Journal:  Clin Transl Sci       Date:  2017-03-14       Impact factor: 4.689

9.  Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients.

Authors:  Johannes Matthaei; Jürgen Brockmöller; Werner Steimer; Konstanze Pischa; Stefan Leucht; Maria Kullmann; Ole Jensen; Typhaine Ouethy; Mladen Vassilev Tzvetkov; Muhammad Rafehi
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

10.  Amitriptyline protects against TNF-α-induced atrophy and reduction in synaptic markers via a Trk-dependent mechanism.

Authors:  Eimear O'Neill; Billy Kwok; Jennifer S Day; Thomas J Connor; Andrew Harkin
Journal:  Pharmacol Res Perspect       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.